CAR-T cells targeting IL-1RAP and their use
US11839630B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 14, 2018 |
| Grant date | Dec 12, 2023 |
| Priority date | — |
| Expiry date | Dec 20, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.